ITP Registry and Accompanying Biospecimen Collection
NCT05152238 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1100
Last updated 2025-07-15
Summary
The objective of this ITP registry is to collect clinical information, including biosampling, from consenting patients with a variety of ITPs at different points in the course of their disease.
Conditions
Sponsors & Collaborators
Principal Investigators
-
Thomas Stauch, Dr. med. · Jena University Hospital
-
Karolin Trautmann-Grill, Dr. med. · Dresden Univeristy Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-11-29
- Primary Completion
- 2026-09-30
- Completion
- 2027-04-30
Countries
- Germany
Study Locations
More Related Trials
-
Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
NCT01196884 ·Status: UNKNOWN
-
This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)
NCT02859909 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT06291415 ·Status: WITHDRAWN ·Phase: PHASE1
-
An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
NCT05333861 ·Status: NOT_YET_RECRUITING
-
Heparin-Induced Thrombocytopenia Registry
NCT00456326 ·Status: COMPLETED
-
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
NCT00102323 ·Status: COMPLETED ·Phase: PHASE3
-
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
NCT03784898 ·Status: COMPLETED ·Phase: PHASE4
-
Alteration of Different Immune Parameters in Immune Thrombocytopenia (ITP) Patients Receiving Eltrombopag Treatment
NCT01864512 ·Status: WITHDRAWN
-
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
NCT00102336 ·Status: COMPLETED ·Phase: PHASE3
-
Investigation on a Dynamic Cohort of Italian Patients With Active ITP
NCT03465020 ·Status: UNKNOWN
-
Longitudinal Observational Study on Immune Thrombocytopenia
NCT07068425 ·Status: NOT_YET_RECRUITING
-
The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
NCT03951623 ·Status: COMPLETED ·Phase: PHASE1
-
An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers
NCT00005570 ·Status: COMPLETED
-
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
NCT04003220 ·Status: UNKNOWN
-
.German TTP-Registry (Thrombotic Thrombocytopenic Purpura)
NCT05389007 ·Status: UNKNOWN
-
The Study of Different Dose Rituximab in the Treatment of ITP
NCT03258866 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Immune Thrombocytopenia Pathogenesis:
NCT02042560 ·Status: COMPLETED
-
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
NCT07059000 ·Status: RECRUITING ·Phase: PHASE3
-
Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)
NCT03469661 ·Status: COMPLETED
-
Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
NCT01178333 ·Status: COMPLETED
-
An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
NCT04943042 ·Status: COMPLETED
-
The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP
NCT03377439 ·Status: UNKNOWN
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
NCT03102593 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
NCT00861692 ·Status: COMPLETED ·Phase: PHASE2
-
Machine-learning Based Prediction Model in Primary Immune Thrombocytopenia
NCT05116423 ·Status: UNKNOWN